New collaboration could help fight neuromuscular diseases
Long-time rivals, the Mayo and the University of Minnesota, have come together to advance the state of Minnesota “as a leader in biotechnology and medical genomics.” The new partnership, naturally called the “Minnesota Partnership for Biotechnology and Medical Genomics,” aims to fund research and drug development for a broad range of conditions, from heart disease and cancer, to transplant rejection and drug addiction. But, also the partnership includes neuromuscular diseases (of which spinal muscular atrophy is) amongst its targets.
